Alloy Therapeutics Announces $40M Series E to Scale Tech-Enabled Biotech Infrastructure

BOSTON — April 15, 2026 — Alloy Therapeutics, Inc. (“Alloy”), a biotechnology ecosystem company powering the future of drug discovery and development through AI-driven platforms and integrated services, today announced a $40 million Series E financing round, marking a significant step in the company’s evolution from antibody discovery pioneer to full-stack biotech infrastructure company. This […]
Alloy Therapeutics Enters into Multi-Target Collaboration and License Agreement with Biogen for Use of Alloy’s AntiClastic™ ASO Platform

Boston, MA, April 7, 2026 — Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting-edge drug discovery technologies, today announced a collaboration and license agreement with Biogen Inc. for the use of Alloy’s novel and proprietary AntiClastic™ ASO Platform. Through this collaboration, Biogen will apply the platform to advance antisense […]
Alloy Therapeutics Appoints Alexander Titus, Ph.D., to Lead New Vigilance Division Focused on Biosecurity and Rapid Therapeutic Response

BOSTON — April 1, 2026 — Alloy Therapeutics today announced that Alexander Titus, Ph.D., has joined the company to lead its newly formed Vigilance Division, a strategic initiative focused on leveraging modern AI capabilities to enhance supply chain resilience, advance biosecurity preparedness, and accelerate the development of therapeutics for emerging biological threats. The Vigilance Division […]
Alloy Therapeutics Enters Into Agreement to Advance Novel Antibody Discovery Platform

BOSTON — March 17, 2026 — Alloy Therapeutics, Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting-edge drug discovery technologies, today announced an agreement with AbbVie to develop a new antibody platform to discover potent, specific, and effective antibodies against targets that are difficult to address with current technologies. As part of […]
Rethinking Antisense Architecture with Transient Cyclic Oligonucleotides for Next-Generation RNA Therapeutics

Author: Christian Cobaugh, CEO, Genetic Medicine Division at Alloy Therapeutics RNA therapeutics are moving from promise to reality. By operating upstream of protein targets and closer to the genetic root causes of many diseases, RNA medicines often offer treatment approaches that differ fundamentally from conventional small molecules or biologics. Antisense molecules have evolved from conceptual […]
Alloy Accelerates Mediar Timeline to the Clinic for Complex Fibrosis Targets

Antibody discovery for complex fibrosis targets requires advanced platforms capable of addressing difficult biology. Alloy Therapeutics partnered with Mediar to accelerate high-quality antibody programs into IND-enabling studies.
Accelerated Antibody Discovery for Complex Fibrosis Targets
Accelerating Antibody Discovery for Challenging Fibrosis Targets Download Case Study Contact Us Advancing a first-in-class fibrosis program against complex biology This case study highlights how Alloy’s antibody discovery platforms and execution model enabled Mediar Therapeutics to move a complex fibrosis program forward with speed and confidence, despite biological and technical barriers that stalled conventional discovery […]
Tahoe Therapeutics and Alloy Therapeutics to Form Joint Venture and Develop First-in-Class Antibody-Drug Conjugates for Hard-to-Treat Cancers

The new company combines Tahoe’s AI-powered target discovery engine with Alloy’s industry-leading ADC development capabilities to advance two first-in-class oncology programs built on deeply validated tumor targets.
Swiss Rockets Group and Alloy Therapeutics Partner to Advance Radioligand Therapeutics in Oncology

Collaboration combines Alloy’s antibody discovery and engineering platforms with Torpedo’s radiopharmaceutical development capabilities – including Terbium-161 – to advance next-generation oncology RLT candidates toward clinical development
Alloy Therapeutics Appoints Christian Cobaugh, Ph.D., as CEO of Alloy Genetic Medicines

BOSTON — January 6, 2026 — Alloy Therapeutics today announced the appointment of Christian Cobaugh, Ph.D., as Chief Executive Officer of Alloy Genetic Medicines. Through its partnerships, the Genetic Medicines division is dedicated to developing AntiClastic™ nucleic acid medicines to treat diseases at the genetic level. Alloy’s AntiClastic technology is a proprietary cyclic nucleic acid […]